Daily Roundup

CU6.ASX 4DX.ASX CVW.ASX MGH.ASX ARU.ASX

Clarity Pharmaceuticals Bolsters Cash Position and Clinical Pipeline

Clarity Pharmaceuticals is firing on all cylinders as it advances its radiopharmaceutical portfolio. The company wrapped up Q2 2026 with a robust cash position of $178.3 million, giving it plenty of runway to push toward commercialization. On the clinical front, things are moving fast—SAR-bisPSMA has now snagged three FDA Fast Track Designations, a significant stamp of approval that could accelerate its path to treating prostate cancer patients. SARTATE is also progressing nicely, with data from both programs presented at major conferences.

Behind the scenes, Clarity has been quietly strengthening its operational muscle. The company inked deals with Nucleus RadioPharma and SpectronRx to expand manufacturing capabilities, ensuring it can scale production when the time comes. On the leadership front, Allison Rossiter joined the board as an independent director, while Dr. Colin Biggin stepped back from his executive role to focus on his position as Chief Operating Officer.

4DMedical Hits Growth Stride with U.S. Expansion and Strong Revenue Gains

4DMedical is making serious headway in both the U.S. and international markets. The company's FY26 operating revenue climbed 23% to $7.2 million, driven by higher scan volumes and margins exceeding 90%—a testament to the strength of its business model. The real excitement, though, is the company's expansion into the U.S. outpatient market through a commercial partnership with SimonMed Imaging, marking a pivotal moment for the company's American ambitions.

On the regulatory front, CT:VQ received TGA approval in Australia, opening the door for commercial deployment down under. The company also completed its acquisition of contextflow GmbH, bolstering its European presence and adding lung cancer screening technologies to its arsenal. Meanwhile, 4DMedical's SaaS products are now humming along at 540 sites globally—a 39% year-over-year jump—with a record quarter of nearly 106,000 scans processed.

Perhaps most compelling is the clinical validation. A study published in the American Journal of Respiratory and Critical Care Medicine showed that CT:VQ-guided patient selection for lung volume reduction surgery achieved a 76% response rate, blowing past the current standard of 46%. With a cash balance of $278 million as of June 30, 4DMedical has the firepower to capitalize on these opportunities.

Rare Earths Play Arafura Locks in Offtake Deals and Secures Funding

Arafura Rare Earths is moving full steam ahead with its Nolans Project. The company announced a Final Investment Decision on May 21, signaling the shift from planning to execution with construction kicking off in September 2026. The Northern Territory Government has also declared the Nolans Project the first-ever Significant Project, a designation that ensures government collaboration and support for regional benefits.

Funding is now firmly in place. Arafura completed a $350 million institutional placement and raised an additional $11.5 million through a Share Purchase Plan. More importantly, the company locked in two binding offtake term sheets—one with Traxys North America and another with an Indian group—each committing to 500 tonnes per annum of NdPr Oxide on an independent pricing index. The company also secured cornerstone equity subscriptions from Export Finance Australia and the German Raw Materials Fund, plus convertible note documentation with the National Reconstruction Fund Corporation. With a total funding requirement of roughly US$1.9 billion, Arafura is well-positioned to become a reliable rare earths supplier.

Maas Group Clears Major Hurdle with ACCC Approval

Maas Group Holdings received a green light from the ACCC for its sale of construction materials business to Heidelberg Materials Australia (HMA), though not without conditions. HMA must divest three concrete plants and a quarry in Queensland and New South Wales to address competition concerns. It's the first Phase 1 decision with conditions under Australia's new merger control regime, which kicked off January 1, 2026.

MGH will pocket up to $1.703 billion in cash—$1.583 billion at settlement and an additional $120 million tied to commercial milestones. The deal still needs to clear a few hurdles: Foreign Investment Review Board approval, standard conditions precedent, and shareholder sign-off at the Annual General Meeting on September 24. Settlement is expected in October 2026.

ClearView Wealth Acquisition by Zurich Now Official

ClearView Wealth Limited confirmed that Zurich Financial Services Australia's acquisition is now effective following Supreme Court approval. Shareholders are in line for two payouts: a special dividend of $0.05 per share on August 12, 2026, and the scheme consideration of $0.60 per share on August 20, 2026. The deal is now moving into implementation mode.